Hydrocortisone reduces Toll-like receptor 4 expression on peripheral CD14+ monocytes in patients undergoing percutanoues coronary intervention

Iranian Biomedical Journal

Volumn 18, Issue 2, 2014, Pages 76-81

  Bagheri, Bahador ^a   Sohrabi, Bahram ^b   Akbar Movassaghpour, Ali ^a   Mashayekhi, Simin ^a   Garjani, Afagh ^a   Shokri, Mehriar ^b   Pezeshkian, Masoud ^b   Garjani, Alireza ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Hydrocortisone; Toll like receptor 4

Indexed keywords

CD14 ANTIGEN; HYDROCORTISONE; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MONOCYTE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS;

AGED; ANTIGENS, CD14; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONOCYTES; PERCUTANEOUS CORONARY INTERVENTION; TOLL-LIKE RECEPTOR 4;

EID: 84893085630     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: 10.6091/ibj.1275.2013     Document Type: Article

References (34)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med; 1999 Jan; 340(2):115-26.
2. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994 May; 89(5):2462-78.
3. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003 Feb; 41(4 Suppl S):15S-22S.
4. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001 Aug; 2(8):675-80.
5. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001 Nov; 1(2):135-45.
6. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of Circulating Toll-Like Receptor 4-Positive Monocytes in Patients with Acute Coronary Syndrome. Circulation. 2005 May; 111(20):2654-61.
7. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol. 2003 Feb; 15(1):5-11.
8. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol. 2000 Jan; 164(2):558-61.
9. Xu X, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001 Dec; 104(25):3103-8.
10. Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells. 2001 Sep; 6(9):733-42.
11. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004 Jul; 101(29):10679-84.
12. Palsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor, Tolllike receptor-4. Immunology. 2004 Oct; 113(2):153-62.
13. Irwin W, Mak S, Mann, DL, Qu R, Penninger JM, Yan A, et al. Tissue expression and immunolocalization of tumor necrosis factor-α in post infarction dysfunctional myocardium. Circulation. 1999 Mar; 99(11): 1492-8.
14. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993 Jan; 328(2): 106-13.
15. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008 Oct; 4(10):525-33.
16. Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation. 2003 Nov; 108(20):2439-45.
17. Bagheri B, Sohrabi B, Movassaghpour A, Mashayekhi S, Garjani A, Shokri M, et al. Monocyte expression of toll-like receptor-4 in patients with stable angina undergoing percutanoeus coronary intervention. Iran J Immunol. 2012 Sep; 9(3):149-58.
18. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kB or activator protein-1: Molecular mechanisms for gene repression. Endocr Rev. 2003 Aug; 24(4):488-522.
19. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: A family affair. Trends Endocrinol Metab. 2008 Nov; 19(9):331-9.
20. Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec; 420(6917):868-74.
21. Libby P, Okamoto Y, Rocha V, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J. 2010 Feb; 74(2):213-20.
22. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105(9):1135-43.
23. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med. 2008 Aug; 18(6):228-32.
24. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002 Mar; 105(10):1158-61.
25. Xu X, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-Like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001 Dec; 104(25):3103-8.
26. Chong A, Shimamoto A, Hampton C, Takayama H, Spring D, Rothnie C, et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004 Aug; 128(2):170-9.
27. Yang J, Jin LY, Ding JW, Zhou YQ, Yang J, Yang R, et al. Expression of Toll-like receptor 4 on peripheral blood mononuclear cells and its effects on patients with acute myocardial infarction treated with thrombolysis. Arch Med Res. 2010 Aug; 41(6):423-9.
28. Versteeg D, Hoefer IE, Schoneveld AH, de Kleijin DP, Busser E, Strijider C, et al. Monocyte Toll-Like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart. 2008 Jun; 94(6):770-6.
29. Inoue T, Komoda H, Kotooka N, Morooka T, Fujimatsu D, Hikichi Y, et al. Increased circulating plateletderived microparticles are associated with stent-induced vascular inflammation. Atherosclerosis. 2008 Jan; 196(1):469-76.
30. Tiong AY, Lowe HC, Freedman SB, Brieger DB. Lack of widespread inflammation after contemporary PCI. Int J Cardiol. 2010 Apr; 140(1):82-7.
31. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000 May; 101(18):2149-53.
32. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev. 2006 Apr; 86(2):515-81.
33. Van der Hoeven BL, Pires NM, Warda HM, Putter H, Quax PH, Schalij MJ, et al. Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and noninsulin-dependent diabetic patients. Int J Cardiol. 2008 Feb; 124(2):166-71.
34. Kakio T, Matsumori A, Ohashi N, Yamada T, Nobuhara M, Saito T, et al. The effect of hydrocortisone on reducing rates of restenosis and target lesion revascularization after coronary stenting less than 3 mm in stent diameter. Intern Med. 2003 Nov; 42(11):1084-9.